NCT02204111
Completed
Not Applicable
Patient Directed Intervention Towards a Multidimensional Recommendation Guideline to Improve the Quality of Life for Patients With Soft Tissue Sarcoma Under Palliative Treatment With Trabectedin
ConditionsSoft Tissue Sarcoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Soft Tissue Sarcoma
- Sponsor
- GWT-TUD GmbH
- Enrollment
- 77
- Locations
- 7
- Primary Endpoint
- Health related QoL, measured by total score of FACT-G
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The primary objective of the study is to compare quality of life (QoL) between patients suffering from soft tissue sarcoma, receiving a multidimensional intervention with those receiving standard treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of advanced or metastatic soft tissue sarcoma
- •Treatment with trabectedin in an in-label prescription
- •Age at least 18 years (inclusive) at the first visit
- •Patients with a life expectancy of at least 6 months
- •The informed consent form must be signed before any study specific tests or procedures are done
- •Confirmation of the subject's health insurance coverage prior to the first visit
- •Ability to understand and follow study-related instructions
Exclusion Criteria
- •ECOG PS \>2
- •Estimated life expectancy of less than 6 months
- •Patients with STS not receiving trabectedin
- •Contraindications according to the local SmPC of Yondelis®
- •Subject is in custody by order of an authority or a court of law
- •Exclusion periods from other studies or simultaneous participation in other clinical studies
- •Previous assignment to treatment during this study
- •Close affiliation with the investigator (e.g. a close relative) or persons working at the study site
- •Subject is an employee of GWT-TUD GmbH or Pharma Mar S.A.
- •Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety
Outcomes
Primary Outcomes
Health related QoL, measured by total score of FACT-G
Time Frame: change to baseline at 9 weeks
assessed by the patient using standard questionnaire (FACT-G) via tablet-PC
Secondary Outcomes
- Anxiety and depression (HADS)(baseline, 9, 21, 35 and 61 weeks)
- Dimensions of QoL (scales of FACT-G)(baseline, 3, 6, 9, 21, 35 and 61 weeks)
- Intensity of pain and pain related interference (BPI)(baseline, 9, 21, 35 and 61 weeks)
- progression free survival(baseline up to 61 weeks)
- Overall survival(baseline up to 61 weeks)
- Satisfaction with care (IN-PATSAT32)(baseline, 9, 21, 35 and 61 weeks)
- Anorexia and cachexia related impact on QoL (FAACT)(baseline, 9, 21, 35 and 61 weeks)
- Severity of cancer-related symptoms (MDASI)(baseline, 3, 6, 9, 21, 35 and 61 weeks)
Study Sites (7)
Loading locations...
Similar Trials
Unknown
Not Applicable
Quality of Life Study for Prostate Cancer PatientsProstate CancerNCT00561444M.D. Anderson Cancer Center1,051
Unknown
Not Applicable
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot StudyRelapsed and/or Refractory Multiple MyelomaNCT03903406Multinational Center for Quality of Life Research, Russia40
Completed
Not Applicable
A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg TabletsRheumatic DiseasesNCT00642837Janssen Korea, Ltd., Korea982
Unknown
Not Applicable
Evaluation of the Quality of Life of Patients Requiring Intestinal Cleansing Using Oral Medications to Imaging Procedure by Patient Reported OutcomeBowel PreparationNCT02536729Fundación Salutia600
Completed
Not Applicable
Craniectomy ProtocolIschemic StrokeDecompressive CraniectomyNCT01990014Nantes University Hospital62